Nivolumab is a programmed cell death 1 (PD-1) antibody that has achieved clinical success in improving recurrence-free survival in a variety of cancers including melanoma [21], hepatocellular carcinoma [22], non-small cell lung cancer [23] and head and neck cancers [24]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.